Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study
帕博利珠单抗与化疗治疗中国非小细胞肺癌且程序性死亡配体1肿瘤比例评分≥1%患者的五年疗效:KEYNOTE-042中国研究
期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.70265
Wu, Yi-Long; Zhang, Li; Fan, Yun; Zhou, JianYing; Zhang, Li; Zhou, Qing; Li, Wei; Hu, ChengPing; Chen, GongYan; Zhang, Xin; Zhou, CaiCun; Arenas, Carmen González; Chen, Zhenghong; Yu, Wen Cheng; Mok, Tony S K